KNA-173

KNA-173 is an investigational gene therapy being developed by Kinea Bio for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a rare, X-linked recessive genetic disorder characterized by progressive muscle degeneration and weakness due to the absence of functional dystrophin protein. KNA-173 is designed to address the underlying cause of the disease by delivering a functional version of the dystrophin gene (typically a truncated micro-dystrophin) to muscle cells using an adeno-associated virus (AAV) vector. The goal of the therapy is to restore dystrophin expression in skeletal and cardiac muscles, thereby improving muscle integrity and slowing the progression of the disease.